Kenvue (KVUE)

Consumer Staples · $37.6B market cap · SEC CIK 0001944048

Next reports on Feb 15, 2027, before the open, with analysts expecting $0.27 in earnings per share.

52-week range $15.94 to $20.13. 4% below its 52-week high and 21% above its low.

The case for KVUE

• Pays a 4.2% dividend while you wait.
• Return on equity of 16%.
• Gross margin of 59% absorbs cost shocks.
• Moves less than the market (beta −0.79).

The case against

• Pricey for its growth: 22.7× earnings, where 1% a year of growth plus a 4.2% dividend would justify about 16×.
• Dividend takes 96% of earnings, leaving little cushion.
• Revenue grew only 1.8%, roughly the pace of inflation.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Consumer Staples companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 36 Consumer Staples companies.

The financials

The financials, five years deep

Pulled from Kenvue's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Kenvue says it does

Company Overview At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world’s largest pure-play consumer health company by revenue with $15.1 billion in Net sales in the fiscal year 2025. By combining the power of science with meaningful consumer insights and our digital strategy, we empower consumers to live healthier lives every day. Built on more than a century of heritage and trusted by generations, our differentiated portfolio of iconic brands—including Aveeno ® , BAND-AID ® Brand, Johnson’s ® , Listerine ® , Neutrogena ® , Nicorette ® , Tylenol ® , and Zyrtec ® —is backed by science and recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands. Our portfolio includes Self Care, Skin Health and Beauty, and Essential Health products, allowing us to connect with consumers…

Risk factors KVUE lists in its 10-K

• Failure to consummate the Proposed Transaction, or a delay in the consummation of the Proposed Transaction, could negatively impact our business, results of operations, financial condition, and stock price
• Holders of our common stock will have a significantly reduced ownership and voting interest in the combined company after the Proposed Transaction and will therefore have less voting influence over the combined company
• Litigation against us or K-C, or the members of our or K-C’s board of directors, could prevent or delay the completion of the Proposed Transaction
• The Merger Agreement restricts our ability to pursue alternatives to the Proposed Transaction
• The need for regulatory approvals may delay the date of completion of the Proposed Transaction or may diminish the benefits of the Proposed Transaction
• If the Proposed Transaction is consummated, its completion is expected to trigger change-in-control or other provisions in certain agreements to which we or K-C is a party
• Failure to integrate our and K-C’s businesses and operations successfully in the expected time frame may adversely affect the future results of the combined company
• The Merger Agreement subjects us to restrictions on our business activities prior to the effective time of the Proposed Transaction
• We have incurred, and will continue to incur, significant costs in connection with the Proposed Transaction, which may be in excess of those we anticipated
• Our brands are critical to our success, and damage to our reputation or our brands could adversely affect us
• We operate in highly competitive product markets and competitive pressures could adversely affect us
• If we are unable to anticipate, understand, and respond appropriately to market trends and rapidly changing consumer and customer preferences in a timely manner, we could be adversely affected
• If our marketing efforts are not successful, we could be adversely affected
• An inability to successfully expand our global operations could adversely affect our business, results of operations, or financial condition
• We face challenges implementing our digital strategy, which could adversely affect us
• Significant challenges or delays in our innovation and development of new products and technologies could adversely affect us
• Counterfeit, intellectual-property-infringing, or other unauthorized versions (“Counterfeit Copies”) of our products, particularly in our OTC business, could harm consumers and adversely affect us
• We rely on third parties in many aspects of our business, including to manufacture certain of our products, which exposes us to additional risks that could adversely affect us
• Disruptions to our manufacturing or supplier operations could adversely affect us
• Disruptions to our distribution operations could adversely affect our ability to deliver our products to consumers and customers
• Volatility in the cost or availability of raw materials and other inputs for our products, including due to military conflicts, has adversely affected, and could in the future continue to adversely affect us
• If we are unable to accurately forecast demand for our products, we could be adversely affected
• We may not fully realize the expected cost savings and/or operating efficiencies associated with our restructuring programs or our strategic initiatives, which could adversely affect us
• An information security incident, including a cybersecurity breach, or the failure of an information technology or operational technology system owned or operated by us or a third party, could adversely affect us
• Our business depends on our ability to attract and retain talented, highly skilled employees who represent our consumers and on the succession of our senior management
• Labor disputes, strikes, work stoppages, or other labor relations matters could adversely affect us
• Climate change, or legal, regulatory, or market measures to address climate change, could adversely affect us
• Increasing scrutiny, emerging legal requirements, and rapidly evolving expectations from stakeholders regarding sustainability matters could adversely affect us
• Insurance coverage, even where available, may not be sufficient to cover losses we may incur
• Significant product returns or refunds could adversely affect us
• We are subject to a broad range of laws and regulations in the United States and globally, and compliance with or enforcement actions related to these laws and regulations could adversely affect us
• We are, and could become, subject to significant legal proceedings and governmental or regulatory investigations that may result in significant expenses, fines, and reputational damage
• Legal proceedings related to talc or talc-containing products, such as Johnson’s
• Baby Powder, sold outside the United States and Canada and other risks and uncertainties related to talc or talc-containing products could adversely affect us
• We may not be able to successfully establish, maintain, protect, and enforce intellectual property rights that are, in the aggregate, material to our business
• A breach of privacy laws or unauthorized access, loss, or misuse of personal data could adversely affect us
• We are subject to a broad range of environmental, health, and safety laws and regulations, and the impact of any obligations under these laws and regulations could adversely affect us
• Changes in tax laws or exposures to additional tax liabilities could adversely affect us
• We face a variety of risks associated with conducting business around the world, including foreign currency fluctuations, and these risks will increase as we continue to expand our global operations
• Acts of war, military actions, terrorist attacks, or civil unrest could adversely affect us
• Uncertain or unfavorable economic or market conditions could adversely affect us
• Impairment of our goodwill and other intangible assets would result in a reduction in net income
• Changes to our credit ratings or disruptions in credit markets or to our banking partners may reduce our access to credit or overall liquidity
• Our historical financial information included herein may not necessarily reflect the results that we would have achieved as an independent, publicly traded company or may not be a reliable indicator of our future results
• We may not achieve some or all of the expected benefits of the Separation, and the Separation could adversely affect us
• Our continued use of legacy J&J branding, including the “Johnson’s
• ” brand, could adversely affect our reputation
• We have incurred and continue to incur charges in connection with the Separation and incremental costs as an independent, publicly traded company
• The transfer of certain assets and liabilities from J&J to us contemplated by the Separation has not been completed and may be significantly delayed or not occur at all
• J&J may fail to perform under the Transition Agreements, or we may fail to have replacement arrangements in place when these agreements expire
• Potential indemnification obligations to J&J in connection with the Separation could adversely affect us
• We may have received better terms from unaffiliated third parties than the terms we will receive in our agreements with J&J
• The stock price of our common stock may fluctuate significantly, and you could lose all or part of your investment in our common stock as a result
• The obligations associated with being an independent, publicly traded company require significant resources and management attention
• Your percentage ownership in us may be diluted in the future
• We have debt obligations that could adversely affect us
• We cannot guarantee the payment of dividends on our common stock, or the timing or amount of any such dividends

Filings

Other Consumer Staples companies